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Abstract
Purpose of Review We summarise the current development of autologous haematopoietic stem cell transplantation (AHSCT) in
treating multiple sclerosis (MS) and discuss future directions for the general neurologist, transplant haematologist and oncologist.
Recent Findings AHSCTwas initially performed to treat MS over 20 years ago. Over recent years, the evidence base has grown,
especially in relapsing-remitting MS (RRMS), with significant improvements in safety and efficacy through better patient
selection, choice of transplant technique and increase in centre experience.
Summary AHSCT is now a treatment option in very carefully selected patients with severe, treatment-resistant RRMS. However,
it is important for transplant haematologists and oncologists to work closely with specialist MS neurologists in patient selection,
during transplant and in long-term follow-up of patients. Data should be registered into international transplant registries and,
ideally, patients should be enrolled on prospective clinical trials in order to build the evidence base and refine transplant
techniques.
Keywords Autologous haematopoietic stem cell transplantation . Multiple sclerosis . Relapsing-remitting multiple sclerosis .
Secondary progressivemultiple sclerosis . Primary progressive multiple sclerosis . Aggressivemultiple sclerosis
Introduction
Multiple sclerosis (MS) is a chronic inflammatory disorder of
the central nervous system (CNS). MS typically presents as a
relapsing-remitting illness. A relapse is a discrete, self-limiting
episode of neurological dysfunction, which is caused by an
acute inflammatory demyelination within the CNS. Although
the clinical features of a relapse may completely resolve, it
usually leaves residual damage to the CNS, which may be
subclinical in nature. Over time, the effect of the repeated
CNS injury accumulates and leads to an irreversible and pro-
gressive neurological dysfunction, with or without
superimposed relapses. Although these neuroinflammatory
and neurodegenerative components run in parallel, the main
pathological process of the relapsing-remitting phase is dom-
inated by neuroinflammation, whereas in the progressive
phase, it evolves into more indolent inflammation with signif-
icant progressive neurodegeneration. In many patients, the
clinical transition from the relapsing-remitting (RR) to the
secondary progressive (SP) phase may take 10–20 years, al-
though in some patients, it can progress more quickly. There
are no diagnostic biomarkers available for the detection of this
transition which remains a retrospective assessment based
largely on clinical observations. This disease model supports
the existence of a ‘therapeutic window’ during which immu-
nomodulatory interventions may prevent or delay the
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progressive, irreversible neurological dysfunction in patients
with RRMS. In 10% of patients, the progressive neurological
dysfunction starts from the onset of the illness, which is
known as primary progressive (PP) MS [1, 2].
Therefore, an ideal therapeutic goal is to switch off the
inflammation and halt disease progression. This is reflected
in a concept that is used by neurologists termed ‘No Evidence
of Disease Activity’ (NEDA); a composite endpoint of three
parameters: absence of clinical relapse, disability progression
and any evidence of radiological disease activity on magnetic
resonance imaging (MRI) [3]. NEDA is achieved with current
disease-modifying therapies (DMTs) to a variable extent.
Immunoablation and reconstitution of the immune system
aiming at switching off the autoreactive, inflammatory process
and restoring self-tolerance is a more intensive approach than
standard DMTs in managing MS [4]. Immunoablation and au-
tologous haematopoietic stem cell transplantation (AHSCT)
was commenced as a MS therapy over two decades ago [5].
International transplant registries have progressively collected
the details of several thousand patients who have received
AHSCT for different forms of MS; for example, the European
Society for Blood and Marrow Transplantation (EBMT) regis-
try has now 1271 patients who have received AHSCT for MS,
which forms the main indication for this treatment in the auto-
immune disease database (personal communication Manuela
Badoglio, EBMTParis Office, September 2018). Recently pub-
lished studies have supported the safe delivery of AHSCT
whilst potentially achieving significantly higher rates of
NEDA compared to DMTs in MS patients with highly active
disease. In this review, we summarise the current evolution of
AHSCT and discuss its future directions.
Efficacy
A variety of conditioning regimens have been used to deliver
AHSCT with variable safety and efficacy profiles, and these
conditioning regimens can be divided in three categories
based on intensity (Table 1) [5, 6••, 7, 8••, 9–15]. Various
studies and historical registry data did not confirm any effica-
cy differences between these conditioning regimens [16–18].
Regardless of the conditioning regimen, AHSCT dramati-
cally reduces annualised relapse rate and MRI disease activity
in MS patients [6••, 13, 14, 19, 20••]. It may take several
months to completely extinguish all MRI inflammatory dis-
ease activities, but evidence suggests that AHSCT is able to
sustain radiological disease remission in the majority of treat-
ed patients [7, 14, 21, 22]. In one study, no clinical or radio-
logical disease activity emerged during up to 13-year follow-
up after immunoablation with a high-intensity conditioning
regimen containing busulfan [6••]. However, breakthrough
disease activity on long-term follow-up has been reportedwith
lesser intensity conditioning regimens [7, 14, 20••, 21, 23].
The reported effect of AHSCT on disability progression
varies among studies. Disability in MS is measured using the
Kurtzke’s Expanded Disability Status Scale (EDSS) (Table 2)
[24]. AHSCT is more effective in preventing disability progres-
sion in RRMS patients than SP MS [25–27]. AHSCT prevents
EDSS deterioration in most treated patients, although in some
cases, EDSS score may start to increase after several years of
disease stability [14, 27–29]. Various natural history studies have
suggested that disability progression is independent of relapses
once a critical EDSS score is reached suggesting that neurode-
generation progresses independent of neuroinflammation
[30–32]. Therefore, AHSCT may not halt disability progression
in the advanced stages of the disease, despite being effective in
reducing relapse rate and inducing radiological disease remis-
sion. The timing at which AHSCT is undertaken during the
disease course is therefore critical to the outcome. As a result,
patients with aggressive disease and shorter duration of disease
are increasingly targeted as prime candidates for clinical trials.
A number of recent phase II studies, using various condition-
ing regimens, have reported AHSCT to be safe and efficacious
over a 3–5-year follow-up period [6••, 13, 19, 20••]. HALT-MS
was a phase II trial, which used BEAM-ATG, an intermediate
intensity conditioning regimen, for immunoablation. In this
study, 73.8% and 69.2% of patients had disease-free survival
(equivalent to NEDA) at 4 and 5 years respectively [19, 20••].
Other studies from Italy, Sweden, Russia andBrazil also reported
that BEAMor BEAM-like regimenswere equally efficacious [7,
18, 27, 33]. An earlier single-centre, phase II trial showed that
AHSCT using a different intermediate intensity conditioning
regimen, 200 mg/kg cyclophosphamide and ATG (Cy-ATG),
was able to achieve NEDA in 62% of cases at 3 years [23]. A
large case series of 145 patients (118 patients with RRMS and 27
patients with SPMS) treated in one centre showed that similar
efficacy figures with 80% and 68% of patients had NEDA at 2
and 4 years respectively [8••]. A Canadian multicentre, phase II
trial showed that AHSCT using a high-intensity conditioning
regimen containing busulfan, cyclophosphamide and ATG was
able to induce NEDA in 69.6% of patients with aggressive dis-
ease at 3 years, although the use of busulfan in the containing
regimen was associated with veno-occlusive disease of the liver
in two patients, one of whom died [6••].
Considering the heterogeneity of the conditioning regimens
and MS phenotypes, an attempt has been made to integrate the
outcomes of the various studies using meta-analysis which re-
ported that NEDA was achieved in 83% (range 70–92%) of
patients at 2 years and 67% (range 59–70%) of patients at 5 years
[34]. However, other data suggested that NEDA could be
sustained over 10 years and beyond [6••, 21, 27]. Although these
studies lack control groups, AHSCT remains highly efficacious
and may be superior to high-efficacy DMTs, such as
Alemtuzumab, Natalizumab, Ocrelizumab and Cladribine
which achieve NEDA in 27–62% of treated patients at 2–
5 years (Table 3) [35–39].
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These encouraging developments need to be considered with
the caveat that there is a lack of fully published randomised
controlled trials (RCTs) directly comparingAHSCTwith current
standard DMTs. The first such trial was the EBMT ‘ASTIMS’
trial which was a multicentre, phase II RCT of AHSCT against
mitoxantrone, an agent which is now rarely used in the era of
biological MS therapy [40•]. In this study, AHSCT was more
effective in reducing MRI disease activity and annualised re-
lapse rate than mitoxantrone over 4 years. The study cohort
was small, and the majority of patients had progressive disease,
Table 2 The Kurtzke’s Expanded
Disability Status Scale (EDSS) Score Description
0 Normal neurological examination of all FS*
1.0 No disability but minimal signs in one FS
1.5 No disability but minimal signs in more than one FSs
2.0 Minimal disability in one FS
2.5 Minimal disability in two FSs
3.0 Fully ambulatory but moderate disability in one FS or minimal disability in three or four FSs
3.5 Fully ambulatory but moderate disability in one FS and minimal disability in one or two FS;
or fully ambulatory with moderate disability in two FSs; or fully ambulatory with minimal
disability in five FSs
4.0 Ambulatory without aid or rest for ≥ 500 m; self-sufficient, up and about some 12 h a day despite
relatively severe disability in one FS or combination of lesser disability levels exceeding limits of
previous steps
4.5 Ambulatory without aid or rest for ≥ 300 m; up and about some 12 h a day despite relatively severe
disability in one FS and combination of lesser disability levels in other FSs exceeding limits of
previous steps
5.0 Ambulatory without aid or rest for ≥ 200 m
5.5 Ambulatory without aid or rest for ≥ 100 m
6.0 Ambulatory with unilateral assistance ≥ 100 m with or without rest
6.5 Ambulatory with bilateral assistance ≥ 20 m without rest
7.0 Only able to ambulate ≤ 5 m with aid, essentially restricted to wheelchair; though wheels self in
standard wheelchair and transfers alone; up and about in wheelchair some ss a day
7.5 Unable to take more than a few steps; restricted to wheelchair and may need aid in transferring and
wheeling self
8.0 Essentially restricted to bed or chair or pushed in wheelchair, but out of bed most of day; retains
many self-care functions; generally, has effective use of arms
8.5 Essentially restricted to bed much of day; has some effective use of arm(s) and retains some
self-care functions
9.0 Helpless and confined to bed; can still communicate and eat
9.5 Totally helpless and confined to bed and totally dependent; unable to communicate effectively or
eat/swallow
10 Death due to MS
*Assessment of EDSS is consist of the examination of eight functional systems (FSs)
Table 1 Categorisation of various conditioning regimens used for AHSCT in MS.
Intensity Conditioning regimen examples Ref
High Total body irradiation, cyclophosphamide and antithymocyte globulin (ATG) [5]
Busulfan, cyclophosphamide and ATG [6••]
Intermediate Carmustine (BiCNU) 300 mg/m2, etoposide 800 mg/m2, cytarabine-arabinoside
800 mg/m2 and melphalan 140 mg/m2 (BEAM) and ATG (BEAM-ATG)
[7]
1. Myeloablative
2. Lymphoablative Cyclophosphamide 200 mg/Kg and rabbit ATG (Cy-ATG) [8••]
Low Cyclophosphamide alone [9]
Melphalan alone [9]
Fludarabine-based regimens [10, 11]
Curr Hematol Malig Rep
and it was therefore not surprising that there was no statistically
significant difference on disability progression.
The ‘MIST’ trial (clinicaltrials.gov identifier: NCT00273364)
is the only multicentre, randomised phase III trial, which is
comparing the efficacy of AHSCT with the best medical
management in patients with RRMS [41•]. In the DMT control
arm, patients were managed with a range of DMTs, but notably
not with the more recently approved Alemtuzumab or
Ocrelizumab. The primary endpoint was treatment failure,
which was defined as an increase of at least 1.0 point of EDSS
sustained for 6 months. With a median follow-up of 2 years
(range 1–5 years), this was observed in 67% of patients in the
DMT arm compared to 6% of patients in the AHSCT arm. The
full report is expected in 2021. However, the question remains as
whether AHSCT is more effective than high-efficacy DMTs,
such as Alemtuzumab or Ocrelizumab.
A number of studies have reported that the reduction of
EDSS score following AHSCT indicated an improvement of
disability [8••, 13, 20••, 27]. This improvement often lasts for
many years, suggesting that if the CNS inflammation is ade-
quately suppressed for a sufficient period of time, functional
recovery may occur, which is mediated not only by the imme-
diate benefits from the arrest of inflammation, but also
through repair and regenerative mechanisms in the longer
term. Once the reserve capacity of a neural network is
completely exhausted, it may lose its ability to make sponta-
neous recovery and to improve its function [42]. Modest im-
provement of EDSS has also been reported with some high-
efficacy DMTs, such as Alemtuzumab [35, 43]. Although
more clinical and scientific evidence is required, the induction
of profound disease remission early in the disease course with
AHSCT followed by partial or complete reversal of disability
contradicts the long-standing notion that disability related to
disease progression in MS is irreversible.
Safety and Tolerability
Early complications of AHSCT include cytopenia, transient
alopecia, fever, engraftment syndrome, mucositis, infection
and other toxicities common to all autologous transplant pro-
cedures [8••, 18]. Transient neurological worsening may also
be a relatively unique feature to this group of patients. In
particular, fever due to ATG and/or infection may exacerbate
neurological symptoms such as pain, spasticity, weakness and
fatigue. Febrile neutropenia or sepsis requires urgent assess-
ment, investigations and treatment with antimicrobial thera-
pies, but also consideration of whether it could be related to
the effect of ATG, which may persist significantly beyond the
conditioning phase. Corticosteroids and paracetamol should
be considered to prevent prolonged pyrexia in the absence of
infection. Peri-transplant-sustained pyrexia regardless of the
presence or absence of infection has been associated with poor
long-term neurological recovery in one study [8••]. Therefore,
prompt action should be considered to prevent prolonged py-
rexia from whatever the cause might be.
Reactivation of varicella-zoster virus is a common late com-
plication, perhaps due to the more intense immunosuppression
associated with ATG used in the conditioning regimen in this
setting. Secondary autoimmune conditions following AHSCT
are encountered with a greater frequency compared to the ma-
lignant disease setting. This includes autoimmune thyroiditis,
immune thrombocytopenic purpura (ITP), rheumatoid arthritis,
Crohn’s disease and acquired anti-factor VIII inhibitor [6••, 16,
25, 28]. However, the rate of secondary autoimmune conditions
with AHSCT appears to be significantly less than treatment
with Alemtuzumab, where almost half of the patients develop
a secondary autoimmune condition [44].
Other late complications include the development of late
malignancy and infertility, which probably occur less
Table 3 Mechanism of action and the rate of yearly NEDAwith high-efficacy DMTs
Drug Mechanism of action Rate of NEDA Ref
Alemtuzumab A humanised monoclonal antibody selectively targeting
CD52 highly expressed on T and B lymphocytes
58.2a–62.4b % at 5 years [35, 36]
Natalizumab α4 integrin antagonist, a selective adhesion molecule inhibitor 27
c
–40d % at 2 years [37]
Ocrelizumab A humanised anti-CD20 antibody 48% at 96 weeks [38]
Cladribine A synthetic deoxyadenosine analogue which induces
a preferential and sustained reduction in numbers of
circulating peripheral T and B lymphocytes
47e % at 96 weeks [39]
These are yearly NEDA rate and likely to significantly higher than cumulative NEDA rate over 5 years
a Patients were treated with DMT prior to participating in the trail
b Patients were treatment naïve before receiving Alemtuzumab
c Patients had non-highly active disease, which was defined as fewer than two relapses or no gadolinium-enhancing lesions at study entry
d Patients had highly active disease, whichwas defined as at least two relapses in the year before study entry and at least one gadolinium-enhancing lesion
at study entry
e Patients were treated with 3.5 or 5.25 mg/kg of Cladribine
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frequently compared to the malignant disease setting. Post-
transplant lymphoproliferative disease, glioblastoma
multiforme, breast cancer, squamous cell carcinoma, prostate
cancer and cervical cancer have been reported so far [16, 22,
25, 28]. AHSCT causes temporary or permanent ovarian and
testicular failure, and patients should be counselled thorough-
ly before AHSCT. Even so, some females treated with
AHSCT for autoimmune diseases naturally conceived preg-
nancies and gave birth to healthy babies [45]. In those circum-
stances, menses recommenced around 3–4 months after
AHSCT [45]. Similarly, men can also father healthy babies
following AHSCT. Fertility conservation procedures, such as
cryopreservation of sperm, egg or embryo should be consid-
ered for all patients undergoing AHSCT. In addition, hormone
replacement therapies should be offered where appropriate.
However, the main concern limiting the use of AHSCT for
MS has been the risk of treatment-related mortality (TRM).
The analysis of the data from EBMT registry revealed a dra-
matic decline in TRM over the last two decades despite the
increased use of AHSCT for MS. The TRM rates were 7.3%
between 1995 and 2000, 1.3% between 2001 and 2007 and
0.7% between 2008 and 2016 [46]. It is also necessary to
recognise that high-efficacy DMTs have various short- and
long-term toxicities, including progressive multifocal
leukoencephalopathy and other serious infective complica-
tions, which are also associated with significant morbidity
and mortality risks [35, 47, 48]. In our centre, even though
we have not had any TRM in MS patients, our practice is to
state to all patients that this procedure is associated with an
approximately 1% risk of TRM, which is also in keeping with
TRM rate for AHSCT across common haemato-oncological
indications, such as myeloma, lymphoma and solid tumours.
It is prudent to inform patients adequately.
‘Intermediate’ conditioning regimens have been the most
widely used conditioning regimens in the EBMT registry. The
international data registries have yet to show any significant
advantage between myeloablative and non-myeloablative
intermediate conditioning regimens, and, in addition, there is
a lack of data about their relative secondary complication
rates [12, 16]. In the EBMT Autoimmune Diseases Working
Party, registry studies are in progress to evaluate outcomes and
safety, including TRM and long-term complication rates (‘late
effects’) in order to help define the best transplant technique in
MS.
Reasons for the Improvement of Efficacy
and Safety
There are three key factors behind the recent improvement in
safety and efficacy of AHSCT: (1) patient selection, (2) choice
of transplant regimen and (3) centre experience.
Patient Selection
Recently, it has become evident that AHSCT is more effica-
cious in patients with RRMS than SPMS or PPMS [25–27].
EBMT registry also reflects these findings, as the proportion
of RRMS patients receiving AHSCT has increased over the
years compared to progressive forms of MS [17]. As an inten-
sive anti-inflammatory treatment, it is far more logical for
AHSCT to be used as an induction therapy for treatment-
refractory aggressive disease rather than a salvage therapy
for progressive forms of MS. The natural history of MS is that
it takes 20 years for patients to lose their ability to ambulate
without assistance and it takes another few years to become
wheelchair bound [30]. Unfortunately, about 4–14% of pa-
tients who have aggressive disease experience an accelerated
disease course [49, 50]. In this group of patients, the disease
progresses three to four times faster. Various terminologies
have been used to describe this phenotype including ‘aggres-
sive’MS, ‘malignant’MS, ‘highly active’MS and ‘fulminant’
MS. The ‘therapeutic window’ in a patient with ‘aggressive’
MS is significantly shorter due to the rapidly progressive na-
ture of the disease and, in reality, it is often a retrospective
diagnosis. If these patients are not treated, they will become
severely disabled within a few years. Early accrual of disabil-
ity is the hallmark of this form of MS. It does not respond to
first-line DMTs such as Beta interferon or Glatiramer acetate
and requires early introduction of Alemtuzumab,
Natalizumab, Cladribine or Cyclophosphamide, but a propor-
tion of patients will not respond even to these drugs [50, 51].
Patients should be closely monitored for treatment failure.
AHSCT should be considered if there is any evidence of
breakthrough disease activity, preferably earlier in the disease
course before irreversible disability develops.
Several other demographic- and disease-related character-
istics also influence the treatment outcome. Younger patients,
shorter disease duration, lower EDSS scores, active inflamma-
tory disease, and absence of other co-morbidity have been
associated with favourable outcomes [8••, 26–28, 52, 53].
These are interlinked; the shorter disease duration means that
patients are likely to be in their relapsing-remitting phase of
illness and thereby also likely to have lower EDSS. In the
absence of any other significant co-morbidity, younger pa-
tients would tolerate the toxic chemotherapy regimen better
than older patients with multiple co-morbidities. As AHSCT
results in rapid cessation of all inflammatory disease activity,
it is not surprising that MS patients with evidence of active
inflammation do better with AHSCT than patients with indo-
lent inflammation. Several reports found that the presence of
gadolinium enhancement at pre-AHSCT MRI was associated
with favourable outcomes, even in patients with the progres-
sive forms of MS [7, 27]. Gadolinium enhancement indicates
a breakdown of the blood-brain-barrier, which may facilitate
the CNS penetration of the conditioning regimen and enhance
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the elimination of autoreactive immune cells. In 2012, the
EBMT published guidelines and recommendations about the
use of AHSCT for MS. These guidelines suggest that AHSCT
may be offered to those patients who have RR disease and
able to ambulate independently, but experience two clinical
relapses with MRI evidence of concurrent disease activity in
the previous year despite the use of standard DMTs. Patients
unable to ambulate independently due to rapid accumulation
of disability from aggressive disease, or occasionally patients
with progressive disease with clear evidence of significant
clinical and MRI disease activities may be considered for
AHSCT even though the benefit in patients with the progres-
sive forms of MS is more limited [12]. In addition to the
guidelines, current consensus also advocates its use in patients
who are below 45 years of age and have disease duration less
than 10 years [54].
Choice of Conditioning Regimen
The myeloablative ‘intermediate’ intensity BEAM-ATG con-
ditioning regimen which was derived from lymphoma treat-
ment regimens has historically been the most popular condi-
tioning regimen in Europe and also widely used in North and
South America [9, 16]. This is used for immunoablation in
patients with MS rather than other autoimmune conditions
treated with AHSCT. Since the publication of the 2012
EBMT guidelines, there has been an increase in use of the
non-myeloablative, intermediate intensity Cy-ATG condition-
ing regimen, which was originally derived from aplastic anae-
mia treatment regimens [55]. It is the generic regimen that is
used for immunoablation in all autoimmune conditions, in-
cluding MS treated with AHSCT. One study attempted to
deescalate the dose of cyclophosphamide in this intermediate
conditioning regimen from 200 to 120 mg/kg, but this regi-
men was unable to suppress the MRI disease activity [15].
Total body irradiation is discouraged due to greater short-
and long-term risks, including infections, secondary malig-
nancies, TRM and EDSS progression possibly due to neuro-
toxicities, and is now rarely used, if at all, inMS. Likewise, the
busulfan containing high-intensity conditioning regimen has
fallen out of use in Europe since the early 2000s [9, 52].
A higher-intensity conditioning regimen is likely to have a
higher efficacy, but this superior efficacy may be offset by its
higher rate of toxicities. Therefore, in clinical practice, a bal-
ance between the intensity and the safety of the treatment has
to be achieved. Two intermediate regimens: the myeloablative
BEAM-ATG and the non-myeloablative Cy-ATG regimens
have shown to induced high rates of sustained NEDA and
no TRM in several recent studies demonstrating a good bal-
ance between efficacy and safety [7, 8••, 20••]. At present,
there is no clear comparative data as to the relative efficacy
and safety of these two most commonly used intermediate
conditioning regimens [16–18] and therefore, EBMT
guidelines advocate using either of these two regimens for
MS [12]. The question of relative superiority between these
two intermediate treatment regimens may be resolved through
registry analysis, but ideally RCTs should be performed.
Centre Experience
Interrogations of the data from the EBMT and the Center for
International Blood and Marrow Transplant Research
(CIBMTR) registries revealed that the TRM was associated
with the experience of the treatment centre [9, 16]. It is rec-
ommended that AHSCT for autoimmune conditions including
MS should be performed by Joint Accreditation Committee
ISCT-Europe & EBMT (JACIE)-approved (or equivalent)
centres. In a transplant centre, the care service is usually tai-
lored for haemato-oncology patients, as they form the major-
ity of the patient population. There needs to be a consideration
for MS specific supportive care measures, including multi-
disciplinary teams, which are likely to develop with the in-
crease in centre experience. Neurologists must have experi-
ence in selecting appropriate candidates for AHSCT, whereas
haematologists need awareness, knowledge and experience of
managing various early treatment-related complications, such
as sustained fever. Although patients typical do not require
any further immunosuppressive therapy, they require long-
term monitoring for various late transplant-related complica-
tions as well as for symptoms and signs of breakthrough dis-
ease activity. MRI brain and/or spine at regular intervals are
required post-transplant, as indolent inflammation may not be
clinically apparent. There are many other additional consider-
ations. For example, many MS patients treated with AHSCT
are in the childbearing age group. Temporary ovarian/
testicular failure and infertility following AHSCT are known
risks and therefore require counselling, and necessary care.
Expert Opinion and Future Prospects
Currently, there are no RCTs comparing the AHSCT with
high-efficacy DMTs. In the UK, a multicentre, randomised,
phase III trial (STAR-MS) will start recruiting patients from
2019 and randomise them to either AHSCTor Alemtuzumab.
Other similar international phase II/III RCTs are also
attempting to address similar key issues, such as RAM-MS
and BEAT-MS. RAM-MS is an international, multicentre,
randomised trial comparing AHSCT with Alemtuzumab
whereas BEAT-MS is a follow-up phase III trial from the
HALT-MS phase II trial. In addition, there is a case for future
clinical trials with novel conditioning regimens that can deliv-
er disease-specific or targeted immunoablation with an aim to
further reduce toxicities whilst maintaining the efficacy com-
pared to the current regimens.
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Health economic evaluation of AHSCT treatment will be
central to financing any publicly or privately funded service.
MS does not only cause a massive burden of costs from long-
term treatment with DMTs, but also reduces long-term quality
of life and leads to unemployment, progressive disability and
eventually dependency, which costs substantially to the indi-
vidual and the health care service. Although AHSCT is not
cheap, it is a one-off treatment and the therapeutic benefits are
likely to sustain for many years suggesting that there may be
major health economic benefits. Hence, health economic stud-
ies evaluating the delivery of AHSCT versus DMTs are need-
ed in the future across a range of health care services.
Another future challenge in the field ofMS is to whether any
benefit can be derived from AHSCT for the progressive forms
of the disease. In the last two decades, a large number of pa-
tients with progressive disease have been treated with AHSCT
[9, 16]. Some studies offer support that AHSCT could reduce
the relapse rate and progression of disability in the progressive
forms of MS, but it is difficult to interpret these studies due to
the lack of control groups [14, 28, 55]. Therefore, this limited
therapeutic benefit must be weighed against the potential
higher rate of TRM associated with advance disability in
SPMS on an individual case basis before offering AHSCT.
Further, RCTs are required to assess the therapeutic benefit of
AHSCT in SPMS. Based on the earlier registry studies,
AHSCT does not appear to be effective in PPMS and therefore
was not recommended in EBMT guidelines [12, 52]. However,
recent studies with DMTs including Beta interferon,
Ocrelizumab and Rituximab have suggested that primary pro-
gressive MS may respond to immunomodulation highlighting
that inflammation plays an important part in progressive phase
of the disease [56–58]. Further studies are required to explore
its potential as a therapy for PPMS.
There are two other avenues in cellular therapy that require
further exploration. For progressive forms of MS, multipotent
mesenchymal stromal cells may have some promise as an
immunomodulator and may also possess the ability to pro-
mote remyelination [59, 60]. Genetic manipulation of
haematopoietic stem cells ex-vivo to develop self-tolerance
against myelin epitopes has also been through early stages
of investigation [61].
Conclusions
AHSCT is now evolving as a highly efficacious and relatively
safe therapeutic option for treatment-refractory RRMS pa-
tients. Whether AHSCT offers a potential cure remains un-
known, and in addition to sustained efficacy, long-term safety
considerations remain of paramount importance. Clinical tri-
als and long-term registry data are required to ascertain the
long-term safety and efficacy of AHSCT over DMTs and to
optimise transplant techniques. Health economic factors, such
as long-term quality of life, employment and costs associated
with treatment and supportive care for AHSCT relative to
DMTs have to be studied for further improvement of patient
care and service. The safety of this treatment has a direct
positive correlation with the experience of the treatment cen-
tre. In addition, a multi-disciplinary team that consists of trans-
plant specialists, MS neurologists, other supporting clinicians
(such as fertility services) and various allied health care pro-
fessionals is essential for the best clinical practice in this field.
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